1h Free Analyst Time
The idiopathic pulmonary fibrosis market is forecast to grow by $1360.99 mn during 2022-2027, accelerating at a CAGR of 6.68% during the forecast period. The report on the idiopathic pulmonary fibrosis market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of respiratory diseases, the growing geriatric population, and the increase in the number of smokers.
The idiopathic pulmonary fibrosis market is segmented as below:
By Route Of Administration
- Oral
- Parenteral
By Drug Class
- Systemic corticosteroids
- Immunosuppressants
- Tyrosine kinase inhibitors
- Anti-fibrotic agents
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the idiopathic pulmonary fibrosis market covers the following areas:
- Idiopathic pulmonary fibrosis market sizing
- Idiopathic pulmonary fibrosis market forecast
- Idiopathic pulmonary fibrosis market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global idiopathic pulmonary fibrosis market: Alembic Pharmaceuticals Ltd., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Ltd., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics Plc, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Liminal BioSciences Inc., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, Shionogi and Co. Ltd., and United Therapeutics Corp.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increase in drug pipeline for IPF.`
According to the report, one of the major drivers for this market is the increasing prevalence of respiratory diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alembic Pharmaceuticals Ltd.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Celix Pharma Ltd.
- Cipla Ltd.
- Daewoong Pharmaceutical Co. Ltd.
- F. Hoffmann La Roche Ltd.
- FibroGen Inc.
- Galapagos NV
- Galecto Inc.
- GNI Group Ltd.
- Horizon Therapeutics Plc
- Intas Pharmaceuticals Ltd.
- Jubilant Pharmova Ltd.
- Liminal BioSciences Inc.
- MediciNova Inc.
- Merck and Co. Inc.
- Mission Therapeutics
- Novartis AG
- Shionogi and Co. Ltd.
- United Therapeutics Corp.
Related Reports
From
Idiopathic Pulmonary Fibrosis Global Market Report 2024
- Report
- 175 Pages
- Global
From
From
From
Idiopathic Pulmonary Fibrosis - Global Strategic Business Report
- Report
- 181 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
